Sunshine Biopharma mRNA Therapeutics Effective at Destroying Cancer Cells
Sunshine Biopharma, Inc. (SBFM) – a pharmaceutical company focused on research, development and commercialization of oncology and antiviral drugs, announced that two of its newly designed mRNA molecules are effective at destroying cancer cells grown in culture.
The cytotoxicity tests were performed on a variety of cancer cells including the following cancers:
- Multidrug resistant breast cancer cells (MCF-7/MDR)
- Ovarian adenocarcinoma cells (OVCAR-3)
- Pancreatic cancer cells (SUIT-2)
Toxicity studies showed that these mRNA molecules had little or no cytotoxic effects. They are adaptable for delivery into patients using the mRNA vaccine technology.
Sunshine Biopharma anticipates filing a patent application in connection with these results soon.
From the CEO of Sunshine Biopharma
Dr. Steve Slilaty, CEO, Sunshine Biopharma, said, “We are delighted by these findings in connection with our ongoing mRNA-as-therapeutic-agents research. The potential use of mRNA to treat cancer opens the door to many possibilities for patients including convenience, reduced toxicity and enhanced efficacy.”
Sunshine Biopharma is working on the development of a treatment for COVID-19 and has completed the synthesis of four potential inhibitors of PLpro and subsequently identified the lead compound called SBFM-PL4.
Sunshine Biopharma Collaboration with the University of Arizona
Recently, the Company’s research efforts are expanded towards finding other PLpro inhibitors by entering into a collaboration agreement with the University of Arizona. The collaboration is focused on determining the in vivo safety, pharmacokinetics, and dose selection properties of three University of Arizona owned PLpro inhibitors, followed by efficacy testing in mice infected with SARS-CoV-2.
Sunshine Biopharma holds the first option to negotiate for a commercial, royalty-bearing license for all intellectual property developed by University of Arizona under the research project.
The firm is also engaged in the development of Adva-27a, a unique anticancer compound. Tests conducted to date have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University’s Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is owner of all patents and intellectual property pertaining to Adva-27a.
Sunshine Biopharma Stock
| Symbol |
SBFM |
| Current Price |
$5.61 |
| Market Cap. |
$38 million |
| 52-Week High |
$62.18 |
| 52-Week Low |
$1.81 |
Prohost Observations
Sunshine Biopharma anticipates filing a patent application in connection with the results that the newly designed mRNA molecules have the capability of destroying cancer cells grown in culture as well as the toxicity studies that show that these mRNA molecules had little or no cytotoxic effects and are adaptable for delivery into patients using the mRNA vaccine technology.
It is important to recognize that these positive tests are early and pre-clinical. Furthermore, we have to recognize the fact that Moderna (MRNA) and BioNTech (BNTX) also have in their Pipelines mRNA therapeutics for cancers and other diseases in addition to the vaccines against COVID-19.
We are following up on Sunshine Biopharma’s activities. We will be ready to take advantage of the firm’s stock’s low price if it comes up with promising clinical trial results. The Company’s research efforts towards finding other PLpro inhibitors through its collaboration agreement with the University of Arizona are encouraing.
Visit our website for more.
Sunshine Biopharma’s New mRNA Therapeutics Killed Cancer Cells with Little or No Adverse Effects
Sunshine Biopharma mRNA Therapeutics Effective at Destroying Cancer Cells
Sunshine Biopharma, Inc. (SBFM) – a pharmaceutical company focused on research, development and commercialization of oncology and antiviral drugs, announced that two of its newly designed mRNA molecules are effective at destroying cancer cells grown in culture.
The cytotoxicity tests were performed on a variety of cancer cells including the following cancers:
Toxicity studies showed that these mRNA molecules had little or no cytotoxic effects. They are adaptable for delivery into patients using the mRNA vaccine technology.
Sunshine Biopharma anticipates filing a patent application in connection with these results soon.
From the CEO of Sunshine Biopharma
Dr. Steve Slilaty, CEO, Sunshine Biopharma, said, “We are delighted by these findings in connection with our ongoing mRNA-as-therapeutic-agents research. The potential use of mRNA to treat cancer opens the door to many possibilities for patients including convenience, reduced toxicity and enhanced efficacy.”
Sunshine Biopharma is working on the development of a treatment for COVID-19 and has completed the synthesis of four potential inhibitors of PLpro and subsequently identified the lead compound called SBFM-PL4.
Sunshine Biopharma Collaboration with the University of Arizona
Recently, the Company’s research efforts are expanded towards finding other PLpro inhibitors by entering into a collaboration agreement with the University of Arizona. The collaboration is focused on determining the in vivo safety, pharmacokinetics, and dose selection properties of three University of Arizona owned PLpro inhibitors, followed by efficacy testing in mice infected with SARS-CoV-2.
Sunshine Biopharma holds the first option to negotiate for a commercial, royalty-bearing license for all intellectual property developed by University of Arizona under the research project.
The firm is also engaged in the development of Adva-27a, a unique anticancer compound. Tests conducted to date have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University’s Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is owner of all patents and intellectual property pertaining to Adva-27a.
Sunshine Biopharma Stock
Prohost Observations
Sunshine Biopharma anticipates filing a patent application in connection with the results that the newly designed mRNA molecules have the capability of destroying cancer cells grown in culture as well as the toxicity studies that show that these mRNA molecules had little or no cytotoxic effects and are adaptable for delivery into patients using the mRNA vaccine technology.
It is important to recognize that these positive tests are early and pre-clinical. Furthermore, we have to recognize the fact that Moderna (MRNA) and BioNTech (BNTX) also have in their Pipelines mRNA therapeutics for cancers and other diseases in addition to the vaccines against COVID-19.
We are following up on Sunshine Biopharma’s activities. We will be ready to take advantage of the firm’s stock’s low price if it comes up with promising clinical trial results. The Company’s research efforts towards finding other PLpro inhibitors through its collaboration agreement with the University of Arizona are encouraing.
Visit our website for more.
Other Articles